Trial Information

Summary: PHI-57 NCI# 7689: Phase I Trial of GTI2040 in Relapsed, Refractory, or High Risk Leukemia and Myelodysplasia

You have been asked to participate in this research study because you have leukemia or myelodysplasia (a blood disorder) that has relapsed (returned after initially responding to chemotherapy) or is refractory (has failed to respond to standard therapy) or you have a high risk acute leukemia or myelodysplasia that would not be effectively treated by standard chemotherapy.  The purpose of this study is to determine the highest dose of the investigational drug GTI2040 that can be given to subjects with relapsed, refractory or high-risk leukemia or myelodysplasia without causing unmanageable side effects.  Another purpose is to do an early evaluation of side effects and possible effects on disease.

Your participation in this study is expected to last at least four weeks (one cycle of treatment).  If you are tolerating treatment and your medical condition is not getting worse, you will be able to receive additional cycles of treatment.  It is anticipated that most subjects will receive this drug for about three months.  After you discontinue treatment, your medical condition will continue to be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 2, 2008 at 2:50:58 PM